Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category, whereas...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A gel-forming antioxidant eye drop for photoreceptor protection in retinitis pigmentosa.

Drug delivery and translational research·2026
Same author

Protocol for NAC Attack, a phase-3, multicenter randomized, parallel, double masked, placebo controlled trial evaluating the efficacy and safety of oral N-acetylcysteine (NAC) in patients with retinitis pigmentosa.

medRxiv : the preprint server for health sciences·2025
Same author

Suppression of choroidal neovascularization by nonviral gene transfer of pigment epithelium-derived factor.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025
Same author

Stair-Case/Honeycomb Maculopathy in Alport Syndrome: A Case Report.

Case reports in ophthalmology·2025
Same author

Sustained Suppression of VEGF for Treatment of Retinal and Choroidal Vascular Diseases.

American journal of ophthalmology·2025
Same author

Structural Updates to the Implant and Refill Needle of the Port Delivery Platform.

Translational vision science & technology·2025
Same journal

Integrative genetic and functional analysis of autosomal dominant hearing loss in 108 multigenerational families.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Preclinical evaluation of cysteine protease-inhibitor aloxistatin (E64d) for heart failure therapy.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Zinc-binding protein metallothionein 3 protects vascular smooth muscle cells from ferroptosis via blocking lysosomal degradation of GPX4.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Clinical utility of cerebrospinal fluid interleukin-10 in central nervous system lymphoma: a molecular neuropathology-informed diagnostic meta-analysis.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Molecular regulation of PGC-1α: from protein-protein interactions and post-translational modifications to pharmacological modulation.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Molecular determinants of thromboinflammatory activation in inflammatory bowel disease.

Journal of molecular medicine (Berlin, Germany)·2026
See all related articles

Related Experiment Video

Updated: May 15, 2026

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography
05:14

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography

Published on: August 11, 2023

Ocular neovascularization.

Peter A Campochiaro1

  • 1Departments of Ophthalmology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21287-9277, USA. pcampo@jhmi.edu

Journal of Molecular Medicine (Berlin, Germany)
|January 19, 2013
PubMed
Summary
This summary is machine-generated.

Vision loss from retinal vascular diseases is common. Treatments targeting vascular endothelial growth factor (VEGF) and platelet-derived growth factor-B (PDGF-B) show promise, with future therapies aiming to target hypoxia-inducible factor-1 (HIF-1).

More Related Videos

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model
09:56

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

Published on: January 21, 2018

An Alkali-burn Injury Model of Corneal Neovascularization in the Mouse
10:52

An Alkali-burn Injury Model of Corneal Neovascularization in the Mouse

Published on: April 7, 2014

Related Experiment Videos

Last Updated: May 15, 2026

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography
05:14

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography

Published on: August 11, 2023

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model
09:56

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

Published on: January 21, 2018

An Alkali-burn Injury Model of Corneal Neovascularization in the Mouse
10:52

An Alkali-burn Injury Model of Corneal Neovascularization in the Mouse

Published on: April 7, 2014

Area of Science:

  • Ophthalmology
  • Vascular Biology
  • Molecular Medicine

Background:

  • Retinal and choroidal vascular diseases are leading causes of vision loss.
  • These diseases involve neovascularization (NV) from retinal or subretinal vessels.
  • Examples include diabetic retinopathy, retinal vein occlusions, retinopathy of prematurity, and neovascular age-related macular degeneration (AMD).

Purpose of the Study:

  • To review the molecular mechanisms underlying retinal and choroidal vascular diseases.
  • To discuss current and future therapeutic strategies targeting these mechanisms.
  • To highlight the role of hypoxia-inducible factor-1 (HIF-1) and its downstream effectors.

Main Methods:

  • Review of existing literature on retinal and choroidal vascular diseases.
  • Analysis of the role of hypoxia and associated signaling pathways (HIF-1, VEGF, PDGF-B).
  • Evaluation of clinical trial data for VEGF antagonists and combination therapies.

Main Results:

  • Retinal hypoxia elevates HIF-1, stimulating pro-angiogenic factors like VEGF and PDGF-B.
  • VEGF antagonists benefit patients with subretinal NV in AMD.
  • Combining VEGF and PDGF-B antagonists yields greater benefits.

Conclusions:

  • Targeting VEGF and PDGF-B is a successful strategy for treating neovascular AMD.
  • Future therapies may involve targeting HIF-1 directly or using gene transfer for anti-angiogenic proteins.
  • Significant progress has been made, with promising future outlooks for patients with these conditions.